Results 241 to 250 of about 4,630,754 (316)

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Corrigendum to “Computational analysis to comprehend the structure-function properties of fibrinolytic enzymes from Bacillus spp for their efficient integration into industrial applications” [Heliyon 10(13), July 2024, e33895]

Heliyon
Nitisha Boro, Pedro Alexandrino Fernandes, Ashis K. Mukherjee   +2 more
doaj   +1 more source

Loss of protein C vs protein S results in discrepant thrombotic phenotypes. [PDF]

Blood Adv
Ku CJ, Yu X, Zhao QY, Grzegorski SJ, Daniel JG, Ferguson AC, Shavit JA.   +6 more
europepmc   +1 more source

Recurrent ischemic strokes caused by hereditary protein S deficiency from a novel PROS1 mutation: a case report. [PDF]

BMC Neurol
Huang MY, Su N, Liu YP, Zhu YC.
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Population-Scale Studies of Protein S Abnormalities and Thrombosis.

JAMA
Chaudhry SA, Haj AK, Ryu J, Jurgens SJ, Rodriguez Espada A, Wang X, Choi SH, Sanna-Cherchi S, Grover SP, Bauer KA, Ellinor PT, Bendapudi PK.   +11 more
europepmc   +1 more source

Protein S Deficiency Unmasked by Young-Onset Stroke: A Case Report. [PDF]

Cureus
Nanda Palanisamy N, Kalyanasundaram BV, Selvam NK.   +2 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Protein-S-nitrosylation of human cytomegalovirus pp65 reduces its ability to undermine cGAS. [PDF]

J Virol
Cox JB, Nukui M, Murphy EA.
europepmc   +1 more source